1. Home
  2. SLN vs ANPA Comparison

SLN vs ANPA Comparison

Compare SLN & ANPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.57

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

ANPA

Rich Sparkle Holdings Limited Ordinary Shares

N/A

Current Price

$23.17

Market Cap

300.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLN
ANPA
Founded
1994
2016
Country
United Kingdom
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.4M
300.0M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
SLN
ANPA
Price
$6.57
$23.17
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$39.67
N/A
AVG Volume (30 Days)
314.1K
15.0K
Earning Date
11-06-2025
09-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$25,830,000.00
$5,832,684.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$299.53
Revenue Growth
40.39
N/A
52 Week Low
$1.97
$2.80
52 Week High
$8.08
$54.75

Technical Indicators

Market Signals
Indicator
SLN
ANPA
Relative Strength Index (RSI) 50.57 N/A
Support Level $5.95 N/A
Resistance Level $6.60 N/A
Average True Range (ATR) 0.53 0.00
MACD -0.03 0.00
Stochastic Oscillator 41.33 0.00

Price Performance

Historical Comparison
SLN
ANPA

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.

Share on Social Networks: